Jean Bennett
Direktor/Vorstandsmitglied bei REGENXBIO INC.
Vermögen: 48 341 $ am 30.04.2024
Aktive Positionen von Jean Bennett
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
REGENXBIO INC. | Direktor/Vorstandsmitglied | 01.03.2021 | - |
Independent Dir/Board Member | 01.03.2021 | - | |
Opus Genetics, Inc.
Opus Genetics, Inc. BiotechnologyHealth Technology Opus Genetics, Inc. is a gene therapy company that focuses on treating inherited retinal diseases. The company is based in Raleigh, NC, and leverages knowledge of the best science and the expertise of pioneers in ocular gene therapy to transparently drive transformative treatments to patients. The company has a unique model and purpose, and is backed by Foundation Fighting Blindness's venture arm, the RD Fund. Opus Genetics has wholly owned programs in numerous orphan retinal diseases, and its AAV-based gene therapy portfolio tackles some of the most neglected forms of inherited blindness while creating novel orphan manufacturing scale and efficiencies. The company was founded in 2021 by Benjamin R. Yerxa, Peter L. Ginsberg, Jason D. Menzo, Jean Bennett, Russell Kelley, Jean Bennett. Benjamin R. Yerxa has been the CEO since 2021. | Direktor/Vorstandsmitglied | 01.02.2021 | - |
Gründer | 01.02.2021 | - | |
Perelman School of Medicine | Corporate Officer/Principal | - | - |
Karriereverlauf von Jean Bennett
Ehemalige bekannte Positionen von Jean Bennett
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Limelight Bio, Inc.
Limelight Bio, Inc. BiotechnologyHealth Technology Limelight Bio, Inc. engages in the development of proprietary technologies, advanced targets, and drug candidates for the expansion of current gene therapy and gene editing approaches. The company was founded by Phil Johnson and Jean Bennett in 2017 and is headquartered in Philadelphia, PA. | Gründer | - | - |
SPARK THERAPEUTICS, INC. | Gründer | - | - |
Gensight Biologics, Inc. | Gründer | - | - |
Center For Advanced Retinal & Ocular Therapies | Direktor/Vorstandsmitglied | - | - |
Ausbildung von Jean Bennett
University of California, Berkeley | Doctorate Degree |
Harvard University | Doctorate Degree |
Yale University | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 11 |
Operativ
Founder | 4 |
Director/Board Member | 3 |
Doctorate Degree | 2 |
Sektoral
Health Technology | 5 |
Consumer Services | 5 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
REGENXBIO INC. | Health Technology |
Private Unternehmen | 5 |
---|---|
Opus Genetics, Inc.
Opus Genetics, Inc. BiotechnologyHealth Technology Opus Genetics, Inc. is a gene therapy company that focuses on treating inherited retinal diseases. The company is based in Raleigh, NC, and leverages knowledge of the best science and the expertise of pioneers in ocular gene therapy to transparently drive transformative treatments to patients. The company has a unique model and purpose, and is backed by Foundation Fighting Blindness's venture arm, the RD Fund. Opus Genetics has wholly owned programs in numerous orphan retinal diseases, and its AAV-based gene therapy portfolio tackles some of the most neglected forms of inherited blindness while creating novel orphan manufacturing scale and efficiencies. The company was founded in 2021 by Benjamin R. Yerxa, Peter L. Ginsberg, Jason D. Menzo, Jean Bennett, Russell Kelley, Jean Bennett. Benjamin R. Yerxa has been the CEO since 2021. | Health Technology |
Center For Advanced Retinal & Ocular Therapies | |
Spark Therapeutics, Inc.
Spark Therapeutics, Inc. BiotechnologyHealth Technology Spark Therapeutics, Inc. engages in the research, development, and commercialization of gene therapies. Its product portfolio intends to treat inherited retinal sickness, liver-mediated, and neurodegenerative diseases. The company was founded by Jean Bennett, Beverly Davidson, Katherine A. High, Jeffrey D. Marrazzo, J. Fraser Wright, and Jennifer Wellman on March 13, 2013 and is headquartered in Philadelphia, PA. | Health Technology |
Gensight Biologics, Inc. | |
Limelight Bio, Inc.
Limelight Bio, Inc. BiotechnologyHealth Technology Limelight Bio, Inc. engages in the development of proprietary technologies, advanced targets, and drug candidates for the expansion of current gene therapy and gene editing approaches. The company was founded by Phil Johnson and Jean Bennett in 2017 and is headquartered in Philadelphia, PA. | Health Technology |
- Börse
- Insiders
- Jean Bennett
- Erfahrung